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Extensively hydrolyzed casein formula containing
Lactobacillus rhamnosus GG reduces the
occurrence of other allergic manifestations
in children with cow’s milk allergy: 3-year
randomized controlled trialRoberto Berni Canani, MD, PhD,a,b,c Margherita Di Costanzo, MD,a Giorgio Bedogni, MD,c,d Antonio Amoroso, BS,a,c
Linda Cosenza, MD,a Carmen Di Scala, LDN,a Viviana Granata, MD,a and Rita Nocerino, RNa,c Naples and Trieste, ItalyBackground: Children with cow’s milk allergy (CMA) have an
increased risk of other allergic manifestations (AMs).
Objective: We performed a parallel-arm randomized controlled
trial to test whether administration of an extensively hydrolyzed
casein formula (EHCF) containing the probiotic Lactobacillus
rhamnosus GG (LGG) can reduce the occurrence of other AMs
in children with CMA.
Methods: Children with IgE-mediated CMAwere randomly
allocated to the EHCF or EHCF1LGG groups and followed for
36 months. The main outcome was occurrence of at least 1 AM
(eczema, urticaria, asthma, and rhinoconjunctivitis). The
secondary outcome was tolerance acquisition, which was defined
as the negativization of a double-blind food challenge results at 12,
24, and36months.AMswerediagnosedaccording to standardized
criteria. Tolerance acquisition was evaluated every 12 months.
Results: A total of 220 children (147 boys [67%]) with a median
age of 5.0 months (interquartile range, 3.0-8.0 months) were
randomized; 110 children were placed in the EHCF group, and
110 children were placed in the EHCF1LGG group. In the
complete case analysis the absolute risk difference for the
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190620.36 to 20.10; P < .001), and the absolute risk difference for
the acquisition of cow’s milk tolerance was 0.20 (95% CI, 0.05-
0.35; P < .01) at 12 months, 0.24 (95% CI, 0.08-0.41; P < .01) at
24 months, and 0.27 (95% CI, 0.11-0.43; P < .001) at 36 months.
In the sensitivity analysis the effect size of the main outcome was
virtually unchanged when the occurrence of AMs was assigned
to all 27 missing children.
Conclusions: EHCF1LGG reduces the incidence of other AMs
and hastens the development of oral tolerance in children with
IgE-mediatedCMA. (JAllergyClin Immunol 2017;139:1906-13.)
Key words: Eczema, urticaria, asthma, rhinoconjunctivitis, atopic
march, food allergy, gut microbiota, probiotics
Discuss this article on the JACI Journal Club blog: www.jaci-
online.blogspot.com.
Food allergy (FA) is a common chronic condition in childhood.1
Recent studies have suggested that the natural history of FA has
changed during the last 2 decades, with an increased prevalence,
severity of clinical manifestations, and risk of persistence into later
ages.2,3 The increased FA prevalence in children has an important
economic effect, with significant direct costs for the health care sys-
tem and even larger costs for the families.4 In addition, children
with FA are at increased risk of having other allergicmanifestations
(AMs) later in life. According to a recent US Centers for Disease
Control and Prevention study, children with FA are 2 to 4 times
more likely to have other AMs, such as asthma (4.0 times), atopic
eczema (2.4 times), and respiratory allergies (3.6 times), compared
with children without FA.5,6
Cow’s milk allergy (CMA) is among the most common FA in
early childhood, with an estimated prevalence of 2% to 3%.7 We
previously showed that in children with CMA, an extensively hy-
drolyzed casein formula (EHCF) supplemented with the probiotic
Lactobacillus rhamnosus GG (LGG) induced higher tolerance
rates compared with EHCF without LGG and other formulas.8,9
These findings were consistent with those of a 1-year follow-up
study performed in the United States that showed better outcomes
with EHCF1LGG- versus EHCF- or amino acid–based formula
for the first-line dietary management of CMA.10 Multiple mech-
anisms might be responsible for the observed clinical effects of
the EHCF1LGG formula. Preliminary data suggested that die-
tary intervention with EHCF1LGG has positive effects on gut
dysbiosis, short-chain fatty acid production,11 and epigenetic
regulation of TH1 and TH2 cytokines gene expression.
12 Such
mechanisms suggest a possible long-term effect on the immune
system of children with CMA treated with EHCF1LGG. The
J ALLERGY CLIN IMMUNOL
VOLUME 139, NUMBER 6
BERNI CANANI ET AL 1907Abbreviations usedAM: Allergic manifestationARD: Absolute risk differenceBRM: Binomial regression modelCCA: Complete case analysisCMA: Cow’s milk allergyDBPCFC: Double-blind, placebo-controlled food challengeEHCF: Extensively hydrolyzed casein formulaFA: Food allergyFP: Family pediatricianHDAC: Histone deacetylaseIQR: Interquartile rangeLGG: Lactobacillus rhamnosus GGRCT: Randomized controlled trialSA-BCS: Sensitivity analysis–best-case scenarioSA-EQS: Sensitivity analysis–equal worst outcome scenarioSA-WCS: Sensitivity analysis–worst-case scenarioSPT: Skin prick testpresent randomized controlled trial (RCT) was designed to test
whether a dietary intervention with EHCF supplemented with




The present parallel-arm RCTwas designed to test whether EHCF1LGG
can reduce the incidence of other AMs compared with EHCF in children with
IgE-mediated CMA. The RCT was performed from October 2008 to
December 2014 in collaboration with family pediatricians (FPs) who care
for children up to 14 years of age in the Italian National Health System.
Before the start of the study, all of the involved FPs attended an investigator
meeting in which the study protocol was illustrated and discussed, and all of
the procedures and definitions were shared.Ethics
The study was approved by the Ethics Committee of the University of
Naples ‘‘Federico II’’ and was registered at at www.clinicaltrials.gov (registra-
tion no. NCT01891916).Study subjects
The design of the study is depicted in Fig 1.
Children who were consecutively observed at FP’s office because the
recent occurrence of signs and symptoms possibly related to IgE-mediated
CMA were sent to our tertiary center for pediatric allergy for possible
inclusion in the study.
The inclusion criteria were age of 1 to 12 months and suspected IgE-
mediated CMA. The exclusion criteria were cow’s milk protein–induced
anaphylaxis, food protein–induced enterocolitis syndrome, other FAs, other
allergic diseases, non–CMA-related atopic eczema, eosinophilic disorders of
the gastrointestinal tract, chronic systemic diseases, congenital cardiac
defects, active tuberculosis, autoimmune diseases, immunodeficiency, chronic
inflammatory bowel diseases, celiac disease, cystic fibrosis, metabolic
diseases, malignancy, chronic pulmonary diseases, malformations of the
gastrointestinal and/or respiratory tract, and administration of prebiotics or
probiotics during the 4 weeks before enrollment.
Only subjects who met the inclusion criteria were invited to participate in
the study. Written informed consent was obtained from the parents/tutors of
each subject. Anamnestic, demographic, anthropometric, and clinical data, as
well as information on sociodemographic factors, family and living condi-
tions, parental history of allergic diseases, maternal smoking duringpregnancy, environmental tobacco smoke exposure, number of siblings, and
pet ownership, were obtained from the parents of each infant and recorded in a
clinical database.
Then skin prick tests (SPTs) were performed, and according to a 1:1
randomization list prepared by a biostatistician who was not involved in the
statistical analysis, infants were randomly allocated to one of 2 groups of
dietary intervention: group 1, who received EHCF (Nutramigen; Mead
Johnson Nutrition, Evansville, Ind), or group 2, who received EHCF
containing LGG (Nutramigen LGG, Mead Johnson Nutrition).
From 2 to 4 weeks after the first assessment, when full and stable
remission of CMA symptoms was achieved, a double-blind, placebo-
controlled food challenge (DBPCFC) was performed. The recruitment
continued until a prespecified number of 110 subjects per group with
DBPCFC-proved IgE-mediated CMA was achieved, and only these
subjects continued the exclusion diet using the hypoallergenic formula
prescribed at randomization.Intervention and data collection
Both study products were commercially available as formula powder for
CMA dietary treatment in Italy. The composition of the 2 formulas was
identical except for the presence of LGG; the price was the same, and the
packaging was very similar. The physical and organoleptic properties of the 2
formulas were identical. The physicians responsible for enrollment of patients
allocated the next available number on entry into the trial.
The dietitians counselled parents about issues that could arise during the
elimination diet and on how to replace cow’s milk with an alternative source of
nutrients to reach the daily recommended intake for Italian children.13 The
parents received a written prescription for an exclusion diet for CMA with
the formula name, daily amount, and preparation instructions, according to
the manufacturer’s specifications. The randomized formulas were directly
purchased by the parents of the children.
Effective use of the formula was evaluated during the study by dietitians
counselling parents about issues that could arise during the elimination diet, but
these dietitians were not involved in evaluation of study outcomes. Parents or
caregivers were asked to keep a daily record of formula use. The amount
prepared (millimeters of water and number of formula spoons) and amount left
after each consumption were recorded in a diary to assess the amount consumed
by the child. This allowed the study staff to evaluate compliance with the
assigned formula and to ensure that the patients received an appropriate quantity
of formula to meet their nutritional requirements.
Then, during a 3-year follow-up, 3 visits (at 12, 24, and 36 months) were
planned. SPTs and oral food challenges were performed to explore tolerance
acquisition to cow’s milk every 12 months. Unscheduled visits were made
when the FP noticed any allergic symptoms. At each visit, the children were
physically examined, body growth was assessed, and a structured interview on
health problems, including allergic symptoms, was carried out. Both
DBPCFCs and clinical examinations were performed at the tertiary center
by 2 investigators blinded to group assignments. In the case of discordance
about an AM diagnosis, further evaluation by a third pediatrician experienced
in pediatric allergy was performed. AMs were diagnosed by using standard-
ized criteria.
Atopic eczema was diagnosed based on pruritus, typical morphology and
distribution, a chronic or chronically relapsing course, and personal or family
atopic history (3 of 4 criteria) in addition to 3 minor criteria among a list of 21,
as previously reported.14
Allergic rhinoconjunctivitis was diagnosed based on the symptoms of
rhinitis, such as nasal congestion, sneezing, itching, rhinorrhea, current use of
medication for these symptoms, and/or conjunctivitis, after exclusion of
infection.15
Allergic urticariawas diagnosed if at least 2 episodes of itching eruptions or
swelling with typical appearance were observed by the parents or a physician
and were caused by the same allergen. In the case of a single episode,
immunologic evidence (SPT with the accused undiluted native allergen
causing a wheal reaction of >_3 mm or an allergen-specific IgE level of >_0.35
KU/L) or a positive provocation response with the suspected allergen was
performed for definitive diagnosis.16
FIG 1. Study design.
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recurrent wheeze (more than once a month), difficulty in breathing, chest
tightness, or both; cough (worse at night); clinical improvement during
treatment with short-acting bronchodilators and inhaled steroids; and
worsening when treatment was stopped. Alternative causes of recurrent
wheezing were considered and excluded.17
IgE-mediated FA was defined as the presence of (1) a clinical history
suggestive of an IgE-mediated mechanism (acute onset of symptoms after the
ingestion of trigger food); (2) DBPCFC findings (occurrence of typical
symptoms within 2 hours after the administration of the last dose); (3)
occurrence of typical symptoms of IgE-mediated FA (ie, pruritus without skin
lesions, urticaria, atopic eczema exacerbation, angioedema, vomiting, diar-
rhea, bloody stools, abdominal pain, rhinitis, nasal congestion, wheeze, cough,
stridor, and difficulty breathing during the challenge); and (3) results of SPTs
(wheal size >3 mm) and/or serum IgE measurements (>0.1 kU/L).1,6,8
Compliance was operationally defined as consumption of at least 80% of
the assigned treatment and was evaluated as previously described at every
follow-up visit by dietitians who were not involved in the evaluation of the
study outcomes.
Study outcomes
The primary outcome was the occurrence of any AM (eczema, urticaria,
asthma, or rhinoconjunctivitis) during the 36 months of the study. The
secondary outcome was the acquisition of tolerance at 12, 24, and 36 months.
The occurrence of any other IgE-mediated FA alone or in combination with
AMs was also recorded.Calculation of sample size
We aimed at detecting a difference of 20% in the incidence of AM in the
EHCF1LGG group versus the EHCF group with a power of 90% at an a level
of .05 (Pearson x2 test). Assuming a missingness rate of 10% at follow-up, this
implies enrollment of 110 children per group. However, because the children
had to have aDBPCFC-confirmedCMAdiagnosis, we had to increase the pool
of children allocated to the 2 treatments, andwe designed the study to enroll up
to 150 children per group until at least 110 children per group had a DBPCFC-
confirmed CMA diagnosis.Study tests
SPTs. SPTs were performed with fresh milk and allergens of cow’s milk
protein, such as a-lactalbumin, b-lactoglobulin, and casein (Lofarma S.p.A,
Milan, Italy). The allergen was applied to the patient’s volar forearm. SPTs
were performed with a 1-mm single peak lancet (ALK-Abello, Copenhagen,
Denmark) with histamine dihydrochloride (10 mg/mL) and an isotonic saline
solution (NaCl 0.9%) as positive and negative controls, respectively. Re-
actions were recorded on the basis of the largest diameter (in millimeters) of
the wheal and flare at 15 minutes. The SPT response was considered
‘‘positive’’ if the wheal was 3 mm or larger without a reaction to the negative
control.
Oral food challenge. All food challenges were performed in a
double-blind, placebo-controlledmanner in the outpatient clinic of the tertiary
center involved in the study on 2 separate days with a 1-week interval. Parents
of infants taking antihistamines were advised to withhold these medications
for 72 hours before and during the challenge. Randomization and preparation
of the challenges were performed by experienced FA dietitians who were not
directly involved in the procedures. In detail, every 20 minutes, increasing
doses (0.1, 0.3, 1, 3, 10, 30, and 100 mL) of fresh pasteurized cow’s milk
containing 3.5% of fat or an amino acid formula were administered. Full
emergency equipment and medications (epinephrine, antihistamines, and
steroids) were available. The results were assessed simultaneously by
experienced pediatric allergists. Study subjects were scored for 9 items
divided into 4 main categories on a 0- to 3-point scale (0, none; 1, light; 2,
moderate; and 3, severe): (1) general (decreased blood pressure plus
tachycardia); (2) skin (rash and urticaria/angioedema); (3) gastrointestinal
(nausea or repeated vomiting, crampy-like abdominal pain, and diarrhea); and
(4) respiratory (sneezing or itching, nasal congestion or rhinorrhea, and stridor
deriving from upper airway obstruction or wheezing). If at least 2 of the 3
physicians independently scored any item at level 3 or 2 (or more) items at
level 2, the test result was considered positive. Clinical symptoms occurring
within 2 hours of administering the highest dose were defined as having
‘‘immediate reactions.’’ Infants were observed for 2 hours after the final dose
and then discharged. In case of a positive DBPCFC result at any testing dose,
the patient remained under observation until symptom resolution. If the patient
did not show any symptoms within the first 24 hours, parents were advised to
provide a single feed of 100mL of the tested formula (verum or placebo) every
FIG 2. Flow of the children through the study.
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BERNI CANANI ET AL 1909day at home for 7 days. If any symptoms occurred during this period, the
patients returned to the outpatient clinic on the same day. After 7 days of
verum or placebo administration, the patients were examined, and the parents
were interviewed at the center. Parents were asked to contact the center if any
symptoms occurred in the 7 days after the DBPCFC procedures to rule out
false-negative challenge results. The challenge result was considered negative
if the patient tolerated the entire challenge, including the observation period.
Clinical tolerance acquisition was defined by the presence of a negative
DBPCFC result. Children with a negative DBPCFC result at any subsequent
visit were re-evaluated after 6 months to check for the persistence of tolerance
acquisition.Statistical analysis
Most continuous variables had non-Gaussian distributions, and all are
reported as medians and interquartile ranges (IQRs). Discrete variables are
reported as counts and proportions or as medians and IQRs.
The main outcome (ie, the effect of EHCF1LGG vs EHCF on the
occurrence of any AM during 36 months) was evaluated by using a binomial
regression model (BRM).18 The response variable of the BRMwas the occur-
rence of any AM during 36 months (discrete: 0 5 no, 1 5 yes), and the pre-
dictor variable was treatment (discrete: 0 5 EHCF, 1 5 EHCF1LGG). The
point estimate and 95% CI of the absolute risk difference (ARD) were ob-
tained from the BRM and inverted to calculate the number needed to treat.19
We also assessed the degree to which the ARD changed after the inclusion of
the following discrete covariables into the BRM: sex (05 female, 15male),
birth at term (discrete: 05 no, 15 yes), cesarean delivery (discrete: 05 no,
15 yes), breast-feeding for at least 2 months (discrete: 05 no, 15 yes), fa-
milial risk of allergy (discrete: 05 no, 15 yes), exposure to passive smoking
(discrete: 0 5 no, 1 5 yes), mother smoking during pregnancy (discrete:
0 5 no, 1 5 yes), and exposure to pets (discrete: 0 5 no, 1 5 yes).
The secondary outcome (ie, the time-specific incidence of CMA tolerance)
was evaluated by using a BRM for repeatedmeasures.20 The response variable
of the BRM was the development of CMA tolerance (discrete: 0 5 no,
1 5 yes), and the predictors were treatment (discrete: 0 5 EHCF,
1 5 EHCF1LGG), time (discrete: 0 5 12 months, 1 5 24 months,
2 5 36 months), and a treatment-by-time interaction (discrete-by-discrete).
Repeated measures were taken into account by using subject-specific
cluster CIs. Three prespecified between-group (EHCF1LGG vs EHCF)within-time (12, 24, and 36 months) contrasts were used to quantify the
time-specific ARDs in CMA tolerance. This corresponds to evaluating the
EHCF1LGG versus LGG difference separately at 12, 24, and 36 months.
The relative ARDs and P values were corrected by using a Bonferroni
correction for the 3 comparisons (contrasts).
In addition to doing a complete case analysis (CCA), we performed a
sensitivity analysis using the following scenarios: (1) all missing values of
EHCF1LGG and EHCF set to the worst outcome (sensitivity analysis–
equal worst-outcome scenario [SA-EQS]); (2) missing values of the
EHCF1LGG group set to the best outcome and missing values of the
EHCF group set to the worst outcome (sensitivity analysis–best-case
scenario [SA-BCS]); and (3) missing values of the EHCF1LGG group set
to the worst outcome and missing values of the EHCF group set to the best
outcome (sensitivity analysis–worst-case scenario [SA-WCS]). The worst
outcome was defined as the occurrence of any AM for the main outcome
and as the absence of tolerance at all time points for the secondary
outcome. The SA-EQS for the main outcome was prespecified by the study
protocol. All other sensitivity analyses were implemented post hoc. Statis-
tical analysis was performed with Stata 14.1 software (StataCorp, College
Station, Tex).RESULTS
The flow of the children during the study is reported in Fig 2.
We designed the study to enroll up to 150 children per group
until at least 110 children per group had a DBPCFC-confirmed
CMA diagnosis (see ‘‘Calculation of sample size’’). A total of 137
of 150 planned children provided 110 cases of DBPCFC-
confirmed CMA in the ECHF group, and 131 of 150 planned
children provided 110 cases of DBPCFC-confirmed CMA in the
ECHF1LGG group. A total of 220 subjects with a DBPCFC-
confirmed diagnosis of IgE-mediated CMA (147 male subjects,
67%) with a median age of 5.0 months (IQR, 3.0-8.0 months)
were enrolled.
All children were from families of middle socioeconomic
status and lived in urban areas. At baseline, the main features of
the study groups were similar (Table I).
TABLE I. Baseline features of the subjects enrolled in the study
Feature EHCF EHCF1LGG
Male sex, no. (%) 75/110 (68.2) 72/110 (65.5)
Cesarean delivery, no. (%) 69/110 (62.7) 66/110 (60.0)
Born at term, no. (%) 101/110 (91.8) 98/110 (89.1)
Weight at birth (kg), median (IQR) 3.4 (3.0 to 3.7) 3.2 (2.9 to 3.5)
Breast-fed for >_2 mo, no. (%) 84/110 (76.4) 77/110 (70.0)
Weaning (mo), median, (IQR) 5.0 (5.0 to 6.0) 5.0 (4.0 to 6.0)
Siblings (count), median (IQR) 1 (0.0 to 1.0) 1 (0.0 to 1.0)
Familial risk of allergy, no. (%) 79/110 (71.8) 75/110 (68.2)
Allergic first-degree relatives (count), median (IQR)* 1 (1 to 2) 1 (1 to 2)
Exposure to passive smoking, no. (%) 39/110 (35.5) 38/110 (34.5)
Mother smoked during pregnancy, no. (%) 41/110 (37.3) 35/110 (31.8)
Exposure to pets, no. (%) 13/110 (11.8) 18/110 (16.4)
Age at CMA diagnosis (mo), median (IQR) 5.0 (3.0 to 8.0) 5.0 (3.0 to 8.0)
Weight at CMA diagnosis (kg), median (IQR) 7.5 (6.1 to 8.6) 7.4 (6.1 to 8.7)
Weight at CMA diagnosis (SDS WHO), median (IQR) 0.16 (20.41 to 0.69) 0.14 (20.45 to 0.79)
Length at CMA diagnosis (m), median (IQR) 0.66 (0.61 to 0.70) 0.66 (0.61 to 0.70)
Length at CMA diagnosis (SDS WHO), median (IQR) 0.05 (20.76 to 0.52) 20.03 (20.56 to 0.94)
BMI at CMA diagnosis (kg/m2), median (IQR) 17.3 (16.2 to 18.1) 17.2 (16.2 to 18.1)
BMI at CMA diagnosis (SDS WHO), median (IQR) 0.29 (20.45 to 0.73) 0.26 (20.48 to 0.66)
Positive prick by prick test result for fresh milk, no. (%) 110/110 (100.0) 110/110 (100.0)
Positive SPT response for a-lactalbumin, no. (%) 96/110 (87.3) 94/110 (85.5)
Positive skin test response for b-lactoglobulin, no. (%) 60/110 (54.5) 70/110 (63.6)
Positive SPT response for casein, no. (%) 49/110 (44.5) 51/110 (46.4)
Gastrointestinal symptoms at CMA onset, no. (%) 61/110 (55.5) 65/110 (59.1)
Cutaneous symptoms at CMA onset, no. (%) 75/110 (68.2) 73/110 (66.4)
Respiratory symptoms at CMA onset, no. (%) 17/110 (15.5) 14/110 (12.7)
SDS, SD score; WHO, World Health Organization.
*Calculated only for the subjects with familial risk of allergy.
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assigned formula). No case of misunderstanding of formula use
was reported. A total of 27 (12%) children were lost during
follow-up: 15 in the EHCF group and 12 in the EHCF1LGG
group. Fourteen children withdrew from the study because their
family changed their city of residence, and 13 withdrew for
unknown reasons (they could not be contacted by the study center
or by the FPs). Of the 15 children lost to follow-up in the EHCF
group, 3 were lost at 12 months, 6 at 24 months, and 6 at
36 months. Of the 12 children lost to follow-up in the
EHCF1LGG group, 2 were lost at 12 months, 5 at 24 months,
and 5 at 36 months. Table E1 in this article’s Online Repository at
www.jacionline.org compares the baseline features of the sub-
jects who completed the study with those of the subjects who
were lost to follow-up.Main outcome
Table II reports the frequency of the main outcome (any AM
during 36 months), of the overall and time-specific frequency of
its components (eczema, urticaria, asthma, and rhinoconjunctivi-
tis), and of the overall frequency of other FAs alone or in combi-
nation with AMs.
The ARD of any AM for EHCF1LGG versus EHCF was (1)
20.23 (95% CI, 20.36 to 20.10; P < .001) at CCA; (2) 20.22
(95% CI, 20.35 to 20.09; P < .001) at SA-EQS; (3) 20.33
(95% CI, 20.45 to 20.21; P < .001) at SA-BCS; and (4) 20.08
(95% CI, 20.21 to 0.04; P 5 .5) at SA-WCS. The SA-EQS esti-
mate was very similar to the CCA estimate. On absolute grounds,
the SA-BCS was 10% higher and the SA-WCS was 15% lower
than the CCA estimate. Even under the worst-case scenario, adifference in favor of EHCF1LGG was still present (8%). By us-
ing the CCA estimate of the ARD, the number needed to treat was
4 (95% CI, 3-10). This means that, compared with EHCF, 4 sub-
jects needed to be treated with EHCF1LGG for 36months to pre-
vent at least 1 AM.
Fig 3 plots the incidence of the main outcomes under CCA.
Table E2 in this article’s Online Repository at www.jacionline.
org shows the effect of selected baseline covariables on the inci-
dence of the main outcome. The effect was negligible in all cases,
being less than 2% in absolute terms and less than 10% in relative
terms.
Fig E1 in this article’s Online Repository at www.jacionline.
org plots the incidence of the components of the main outcome
during the study, as determined by CCA. This is an exploratory
analysis performed because the main outcome is a composite
outcome and should therefore only be used for hypothesis-
generating purposes.Secondary outcome
The ARD of cow’s milk tolerance for EHCF1LGG versus
LGGwas (1) 0.20 (95%CI, 0.05-0.35; P <.01) at 12 months, 0.24
(95% CI, 0.08-0.41; P < .01) at 24 months, and 0.27 (95% CI,
0.11-0.43; P < .001) at 36 months by using CCA; (2) 0.15 (95%
CI, 0.00-0.31; P 5 .06) at 12 months, 0.20 (95% CI, 0.05-0.35;
P < .01) at 24 months, and 0.23 (95% CI, 0.09-0.37; P < .001)
at 36 months by using SA-EQS; (3) 0.29 (95% CI 0.15 to 0.43,
P < .001) at 12 months, 0.34 (95% CI, 0.18-0.49; P < .001) at
24 months and 0.36 (95% CI, 0.22-0.51; P < .001) at 36 months
by using SA-BCS; and (4) 0.05 (95% CI, 20.11 to 0.20;
P 5 1.0) at 12 months, 0.09 (95% CI, 20.07 to 0.25; P 5 .5) at
TABLE II. Frequency of the main outcome, its components,
and other FAs
EHCF EHCF1LGG
No. Percent No. Percent
Eczema at 12 mo
No 78 82.1 84 85.7
Yes 17 17.9 14 14.3
Total 95 100.0 98 100.0
Eczema at 24 mo
No 92 96.8 98 100.0
Yes 3 3.2 0 0.0
Total 95 100.0 98 100.0
Eczema at 36 mo
No 89 93.7 97 99.0
Yes 6 6.3 1 1.0
Total 95 100.0 98 100.0
Eczema total episodes
No 69 72.6 83 84.7
Yes 26 27.4 15 15.3
Total 95 100.0 98 100.0
Urticaria at 12 mo
No 77 81.1 94 95.9
Yes 18 18.9 4 4.1
Total 95 100.0 98 100.0
Urticaria at 24 mo
No 95 100.0 96 98.0
Yes 0 0.0 2 2.0
Total 95 100.0 98 100.0
Urticaria at 36 mo
No 93 97.9 96 98.0
Yes 2 2.1 2 2.0
Total 95 100.0 98 100.0
Urticaria total episodes*
No 75 78.9 90 91.8
Yes 20 21.1 8 8.2
Total 95 100.0 98 100.0
Asthma at 12 mo
No 93 97.9 92 93.9
Yes 2 2.1 6 6.1
Total 95 100.0 98 100.0
Asthma at 24 mo
No 87 91.6 96 98.0
Yes 8 8.4 2 2.0
Total 95 100.0 98 100.0
Asthma at 36 mo
No 87 91.6 97 99.0
Yes 8 8.4 1 1.0
Total 95 100.0 98 100.0
Asthma total episodes
No 77 81.1 89 90.8
Yes 18 18.9 9 9.2
Total 95 100.0 98 100.0
Rhinoconjunctivitis at 12 mo
No 90 94.7 93 94.9
Yes 5 5.3 5 5.1
Total 95 100.0 98 100.0
Rhinoconjunctivitis at 24 mo
No 92 96.8 97 99.0
Yes 3 3.2 1 1.0
Total 95 100.0 98 100.0
Rhinoconjunctivitis at 36 mo
No 79 83.2 96 98.0
Yes 16 16.8 2 2.0




No. Percent No. Percent
Rhinoconjunctivitis total episodes
No 71 74.7 90 91.8
Yes 24 25.3 8 8.2
Total 95 100.0 98 100.0
At least 1 allergic episode during the study
No 51 53.7 75 76.5
Yes 44 46.3 23 23.5
Total 95 100.0 98 100.0
Other FAs, total episodes
No 58 61.1 66 67.3
Yes 37 38.9 32 32.7
Total 95 100.0 98 100.0
Other FA plus AMs during the study
No 34 35.8 50 51.0
Yes 61 64.2 48 49.0
Total 95 100.0 98 100.0
*All cases were related to FA.
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by using SA-WCS. Even under the worst-case scenario (SA-
WCS), there was a difference in favor of the ECHF1LGG group.
This differencewas 12% at 24months. Fig 4 plots the incidence of
CMA tolerance in the 2 study groups during the study. As plotted
in Fig E2 in this article’s Online Repository at www.jacionline.
org, the SPT response negativization rate closely mirrored the
tolerance acquisition rate.
Table II reports the overall frequency of other FAs alone or in
combination with AM.Safety
No child was intolerant to the study formulas. No case of
placebo refusal was observed during DBPCFCs. No adverse event
was attributed to the consumption of the formulas, and no
difference was detected in their daily intake. Moreover, the
time-related changes in weight, length, and height were compa-
rable between the EHCF1LGG and EHCF groups (data not
shown).DISCUSSION
A recent systematic review confirmed that early-life food
sensitization leads to other AMs, especially asthma, atopic
eczema, and rhinoconjunctivitis. The authors of this review
concluded that early-life food sensitization should be used as a
marker for developing subsequent allergic diseases that might
benefit from preventive strategies.21 Current knowledge suggests
that allergic diseases are partly determined by an interaction be-
tween genetic and environmental factors during early life, with
amajor role played by the gut microbiota and epigenetics. Among
the epigenetic mechanisms potentially responsible for the devel-
opment of allergic diseases, DNA methylation is the most prom-
inent and extensively investigated.22
The present study was aimed at evaluating whether
EHCF1LGG is more effective than EHCF alone at reducing
the occurrence of other AMs in childrenwith IgE-mediated CMA.
The results of the present RCT shows that EHCF1LGG is more
FIG 3. Incidence of the main study outcome at CCA.
FIG 4. Incidence of CMA tolerance at CCA.
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As far as the primary outcome is concerned, the number of
children needed to treat with EHCF1LGG to prevent the
occurrence of at least 1 AM during the 36-month period was
estimated to be 4 (95% CI, 3-10) by the present study. Although it
is of interest to observe that EHCF1LGG affected all of the
components of the main study outcome, these findings can be
taken only as exploratory, and further studies are necessary to
investigate the potential of this strategy against any single allergic
disease.
The ability of EHCF to prevent allergy is supported by the
results of the German Infant Nutritional Intervention study,16,23-26
in which infants at high risk of allergic diseases were protected
from AMs when they received EHCF. Moreover, EHCF was the
only formula that reduced the incidence of asthma at 15 years
of age.26 Our results show that in a population at higher risk for
other allergies, because of the underlying IgE-mediated CMA,
the addition of LGG to EHCF further enhances the protective ef-
fect of EHCF.
Some relevant insights were derived from our secondary
outcomes. In keeping with previous observations, we provide
additional evidence on the positive effect elicited by
EHCF1LGG on oral tolerance acquisition in children with IgE-
mediated CMA.8-10 In the present study we also showed that this
effect is sustained until 36 months of intervention. These data are
relevant considering the most recent evidence suggesting that the
natural history of CMA has changed over time, with a higher pro-
portion of children with disease persistence through 5 years and
subsequent ages.2,27
Another relevant aspect for clinical practice is that we did not
observe any adverse reactions to the study formulas. These
findings do not agree with those obtained from small case series,
showing that up to 10% of children with CMA could react
adversely to EHCF.28,29 A possible reason for this discrepancy is
that in the present RCT we adopted strict exclusion criteria,
including CMA-related anaphylaxis, eosinophilic gastrointestinal
disorders, and multiple FAs. Our findings support recent guide-
lines suggesting the use of EHCF as a first-line treatment for
CMA, with the exception of patients with CMA-related
anaphylaxis.6,30-32
This study has several strengths. First, it is an RCT that was
performed on a large sample of children with DBPCFC-proved
CMA followed at a tertiary pediatric allergy center with a highfollow-up rate. Second, the effect sizes associated with both the
primary and secondary outcomes were clinically relevant. Third,
such effect sizes maintained a clear trend toward benefit under the
worst-case scenario sensitivity analysis.
Nonetheless, this study has some limitations. First, our data
cannot be generalized to children with conditions that were
reasons for exclusion from the study. The effect of EHCF1LGG
versus EHCF in these children will have to be addressed by
further studies. Second, although our results showed that
EHCF1LGG reduces the incidence of other AMs and favors
the development of oral tolerance in children with IgE-mediated
CMA at 12, 24, and 36months, longer follow-up times are needed
to test whether this effect persists over the long term. Third, our
results are limited by the lack of data obtained in the study
population on the gut microbiota and TH1/TH2 cytokines, which
would be useful to investigate the mechanisms through which
EHCF1LGG produces its effect.
The transitional gut microbiota in the first year of life is
relevant to the development of allergy.33 Evidence obtained by
our group suggests that EHCF1LGG, but not EHCF alone, is
able to increase the abundance of selected genera with the poten-
tial to produce butyrate in infants with CMA.11 Strain-level de-
marcations for butyrate-producing genera (including Roseburia,
Coprococcus, and Blautia) identified in infants that acquired
tolerance to cow’s milk suggest that LGG treatment contributes
to acquisition of tolerance by altering the strain-level community
structure of taxa with the potential to produce butyrate.11 The
mechanisms of action of butyrate against allergy are multiple,
but many involve an epigenetic regulation of gene expression
through inhibition of histone deacetylase (HDAC). Inhibition of
HDAC9 and HDAC6 increases forkhead box P3 gene expression,
as well as the production and suppressive function of regulatory T
cells.34,35 We observed that children with CMA treated with
EHCF1LGG, who acquired oral tolerance, showed a different
TH1/TH2 cytokine and forkhead box P3 gene DNA methylation
pattern compared with patients with CMA treated with other for-
mulas. This pattern was more closely related to that observed in
healthy control subjects. When we analyzed the factors that
potentially influenced the cytokine DNA methylation rate in pa-
tients who outgrew CMA, we found that the only variable was
EHCF1LGG use.12,36 These findings suggested that the positive
action of EHCF1LGG observed in the present RCT could be at
least in part due to a favorable modulation of gut microbiota
and epigenetic mechanisms.
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characterized population of children with IgE-mediated CMA,
shows that EHCF1LGG is superior to EHCF for the prevention of
AMs during a period of 36 months. Further studies are needed to
test whether EHCF1LGG can prevent a single AM, something
that is suggested but cannot be proved by the present RCT, and to
better elucidate themechanisms of this beneficial effect. Our RCT
also confirmed that the addition of LGG to EHCF speeds up the
time to development of tolerance in children with IgE-mediated
CMA.
We thank the children and families for their participation in the study, as
well as the FPs team for the excellent work.
Clinical implications: EHCF1LGG is superior to EHCF for the
prevention of AMs in children with IgE-mediated CMA. The
addition of LGG to EHCF speeds the development of oral
tolerance.
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FIG E1. Exploratory analysis of the incidence of components of the main outcome (eczema, urticaria,
asthma, and rhinoconjunctivitis) during the study period.
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FIG E2. Incidence of SPT response negativization during the study period.
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TABLE E1. Comparison of the features of subjects who completed the study with those of subjects lost to follow-up
Study completers Lost to follow-up
Male sex, no. (%) 130/193 (67.4) 17/27 (63.0)
Cesarean delivery, no. (%) 118/193 (61.1) 17/27 (63.0)
Born at term, no. (%) 172/193 (89.1) 27/27 (100.0)
Weight at birth (kg), median (IQR) 3.3 (3.0 to 3.5) 3.2 (2.8 to 3.5)
Breast-fed for >_2 mo 146/193 (75.6) 15/27 (55.6)
Weaning (mo), median (IQR) 5.0 (4.0 to 6.0) 5.0 (5.0 to 6.0)
Siblings (count), median (IQR) 1 (0 to 1) 0 (0 to 1)
Familial risk of allergy 140/193 (72.5) 14/27 (51.9)
Allergic first-degree relatives (count), median (IQR)* 1 (1 to 2) 1 (1 to 1)
Exposure to passive smoking, no. (%) 69/193 (35.8) 8/27 (29.6)
Mother smoked during pregnancy, no. (%) 61/193 (31.6) 15/27 (55.6)
Exposure to pets, no. (%) 26/193 (13.5) 5/27 (18.5)
Age at CMA diagnosis (mo), median (IQR) 5.0 (3.0 to 7.0) 7.0 (6.0 to 8.0)
Weight at CMA diagnosis (kg), median (IQR) 7.2 (5.9 to 8.6) 8.1 (7.7 to 9.4)
Weight at CMA diagnosis (SDS WHO), median (IQR) 1.92 (1.28 to 2.47) 2.24 (1.72 to 2.64)
Length at CMA diagnosis (m), median (IQR) 0.65 (0.60 to 0.69) 0.69 (0.67 to 0.71)
Length at CMA diagnosis (SDS WHO), median (IQR) 2.69 (1.68 to 3.77) 3.05 (2.73 to 3.42)
BMI at CMA diagnosis (kg/m2), median (IQR) 17.2 (16.1 to 18.0) 18.0 (16.9 to 18.9)
BMI at CMA diagnosis (SDS WHO), median (IQR) 0.58 (0.07 to 1.07) 0.74 (20.03 to 1.25)
Positive prick by prick test result for fresh milk 193/193 (100.0) 27/27 (100.0)
Positive SPT response for a-lactalbumin 163/193 (84.5) 27/27 (100.0)
Positive skin test response for b-lactoglobulin 103/193 (53.4) 27/27 (100.0)
Positive SPT response for casein 73/193 (37.8) 27/27 (100.0)
Gastrointestinal symptoms at CMA onset 109/193 (56.5) 17/27 (63)
Cutaneous symptoms at CMA onset 135/193 (69.9) 13/27 (48.1)
Respiratory symptoms at CMA onset 22/193 (11.4) 9/27 (33.3)
SDS, SD score; WHO, World Health Organization.
*Calculated only for the subjects with familial risk of allergy.
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Breast-fed for at least 2 mo 20.02
(20.17 to 0.13)
Familial risk of allergy 0.22
(0.10 to 0.34)






Exposed to pets 0.15
(20.05 to 0.35)
Observations 193 193 193 193 193 193 193 193
Values are ARDs, with 95% CIs in brackets.
*P < .05.
P < .01.
P < .001.
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